Now in various stages of clinical development, the programs in our pipeline are focused on autoinflammatory and autoimmune diseases with unmet needs, and have the potential to address multiple therapeutic areas.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept IL-1α & IL-1β Recurrent pericarditis
(breakthrough therapy designation)
Mid Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab GM-CSFRα Giant cell arteritis Phase 2
Relapsed or refractory large B-cell lymphoma* End Phase 1
KPL-716 OSMRβ Prurigo nodularis Phase 2
Multi-indication pilot study in diseases with a chronic pruritic component Phase 2
KPL-404 CD40 T-cell dependent, B-cell–mediated indications Phase 1
*Collaboration with Kite Pharma, Inc., a Gilead Company.
KITE is a trademark of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.

Every Second Counts!